Ad hoc: Biofrontera AG: Biofrontera AG decides to increase its base capital
(Thomson Reuters ONE) - Biofrontera AG / Capital increase / Ad hoc: Biofrontera AG decides to increase its base capital Ad hoc announcement according to §15 WpHG processed and transmitted by Hugin. The issuer is solely responsible for the content of this announcement. ------------------------------------------------------------------------------------Leverkusen, 24 July 2009 - Biofrontera AG has decided today toincrease the base capital of the company by up to ? 1,493,757.00through selling up to 1,493,757 new name shares from the authorizedcapital.The shareholders will be offered a purchase right for up to 1,434,157new shares at a price of ? 1.50 per share. The VEM Aktienbank AG,Munich, will be authorized to implement the capital increase.The purchase right will commence on July 29, 2009 and conclude onAugust 11, 2009. A purchase right was suspended for ? 59,600.00fractional shares. Further details on the capital increase will becommunicated in the detailed purchase offer that will be published inthe electronic Federal Bulletin on July 28, 2009.After yesterday's bond holder meeting of Biofrontera AG's 8%convertible bond 2005/2010 the premises for a capital increase havegreatly improved. The bond holders have decided to extend the bonduntil July 02, 2012, and to waive all interest payments from August26, 2008, until August 25, 2011. Therefore, the obligation ofshort-term payments in the amount of ? 1.5 mln., related to theconvertible bond, could be avoided.Due to these changes in the conditions of the convertible, bond newcapital can be almost fully devoted to the operations of Biofrontera.The most relevant goals are the launch of the new product Belixos® inthe fall 2009, as well as conclusion of the clinical developmentprogram, particularly for Biofrontera's actinic keratosis drug BF-200ALA.Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen, GermanyISIN: DE0006046113, WKN: 604611Contact:Anke zur MühlenBiofrontera AGTel.: +49 (0214) 87 63 222Fax.: +49 (0214) 87 63 290E-mail: a.zurmuehlen(at)biofrontera.com --- End of Message ---Biofrontera AGHemmelrather Weg 201 Leverkusen GermanyWKN: 604611; ISIN: DE0006046113; Listed: Freiverkehr in Börse Berlin, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Stuttgart, Open Market in Frankfurter Wertpapierbörse, Regulierter Markt in Börse Düsseldorf;
Datum: 24.07.2009 - 18:42 Uhr
Sprache: Deutsch
News-ID 3969
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 224 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Ad hoc: Biofrontera AG: Biofrontera AG decides to increase its base capital"
steht unter der journalistisch-redaktionellen Verantwortung von
Biofrontera AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
